Form 4: Apellis Pharmaceuticals Executive David O. Watson Reports Changes in Beneficial Ownership

David O. Watson, General Counsel of Apellis Pharmaceuticals, reports changes in his beneficial ownership of company stock due to a distribution from a trust.

Summary

• On September 27, 2024, David O. Watson, General Counsel of Apellis Pharmaceuticals, reported changes in his beneficial ownership of the company's common stock.
• He received 10,569 shares from The David O. Watson Irrevocable Trust of 2023, increasing his direct holdings.
• Following the transaction, Watson directly owns 117,721 shares of Apellis Pharmaceuticals common stock.
• He also has indirect ownership through The David O. Watson Irrevocable Trust of 2023 (70,136 shares), a custodial account for his son (3,333 shares), and The Watson Education Trust (6,667 shares).
• Watson disclaims beneficial ownership of shares held by The David O. Watson Irrevocable Trust of 2023 and The Watson Education Trust except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The increase in direct ownership could be interpreted as a sign of confidence in the company.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders.

Stakeholder Impact

• Shareholders are informed about changes in insider ownership.

Key Dates